N6-methyladenine-modified DNA was decreased in Alzheimer's disease patients.

ABSTRACT:

Background

In recent years, the prevalence of Alzheimer's disease (AD) has increased, which places a great burden on society and families and creates considerable challenges for medical services. N6-methyladenine (m6A) deoxyribonucleic acid (DNA) adenine methylation is a novel biomarker and is abundant in the brain, but less common in AD. We support to analyze the relationship between DNA m6A and cognition in patients with AD and normal controls (NCs) in China.

Aim

To analyze the relationship between the novel m6A DNA and cognition in patients with AD and NCs in China.

Methods

A total of 179 AD patients (mean age 71.60 ± 9.89 years; males: 91; females: 88) and 147 NCs (mean age 69.59 ± 11.22 years; males: 77; females: 70) who were age- and sex-matched were included in

SUBMITTER: Lv S 

PROVIDER: S-EPMC8771380 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature